BRPI0607536A2 - tratamento de dor - Google Patents

tratamento de dor

Info

Publication number
BRPI0607536A2
BRPI0607536A2 BRPI0607536-3A BRPI0607536A BRPI0607536A2 BR PI0607536 A2 BRPI0607536 A2 BR PI0607536A2 BR PI0607536 A BRPI0607536 A BR PI0607536A BR PI0607536 A2 BRPI0607536 A2 BR PI0607536A2
Authority
BR
Brazil
Prior art keywords
pain
treating
treatment
pain treatment
mammal
Prior art date
Application number
BRPI0607536-3A
Other languages
English (en)
Inventor
Sharon Rozenzweig
Michael R Brandt
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BRPI0607536A2 publication Critical patent/BRPI0607536A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)

Abstract

TRATAMENTO DE DOR. A presente invenção refere-se a um método de tratar dor em um mamífero, que inclui administrar a um mamífero em necessidade de tal tratamento, uma quantidade eficaz para tratar dor de um composto da fórmula I: ou um sal farmaceuticamente aceitável deste, em que cada de R^ 1^, R^ 2^, R^ 3^, n, y, e Ar é como definido e descrito aqui. A presente invenção também refere-se a composições farmacêuticas para tratar dor contendo uma quantidade eficaz do composto de fórmula I para tratar dor.
BRPI0607536-3A 2005-04-22 2006-04-21 tratamento de dor BRPI0607536A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67408705P 2005-04-22 2005-04-22
PCT/US2006/015217 WO2006116171A1 (en) 2005-04-22 2006-04-21 Treatment of pain

Publications (1)

Publication Number Publication Date
BRPI0607536A2 true BRPI0607536A2 (pt) 2009-09-15

Family

ID=36793862

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0607536-3A BRPI0607536A2 (pt) 2005-04-22 2006-04-21 tratamento de dor

Country Status (11)

Country Link
US (1) US20060258713A1 (pt)
EP (1) EP1871354A1 (pt)
JP (1) JP2008538578A (pt)
CN (1) CN101189004A (pt)
AU (1) AU2006239943A1 (pt)
BR (1) BRPI0607536A2 (pt)
CA (1) CA2605117A1 (pt)
GT (1) GT200600160A (pt)
MX (1) MX2007013023A (pt)
TW (1) TW200639159A (pt)
WO (1) WO2006116171A1 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050261347A1 (en) * 2003-10-24 2005-11-24 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
US7435837B2 (en) * 2003-10-24 2008-10-14 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
GT200500296A (es) * 2004-10-21 2006-10-02 Sintesis asimetrica de derivados del dehidrobenzofurano
GT200500297A (es) * 2004-10-21 2006-10-27 Sintesis asimetrica de dehidrobenzofuranos sustituidos
WO2006116165A1 (en) * 2005-04-22 2006-11-02 Wyeth Chromane and chromene derivatives and uses thereof
CA2605580A1 (en) * 2005-04-22 2006-11-02 Wyeth Benzodioxane and benzodioxolane derivatives and uses thereof
AR055916A1 (es) * 2005-04-22 2007-09-12 Wyeth Corp Derivados de dihidrobenzofurano, usos de los mismos en la preparacion de un medicamento y composicion farmaceutica
TW200718692A (en) * 2005-04-22 2007-05-16 Wyeth Corp Dihydrobenzofuran derivatives and uses thereof
WO2006116221A2 (en) * 2005-04-22 2006-11-02 Wyeth Therapeutic combinations for the treatment or prevention of psychotic disorders
US7368477B2 (en) * 2005-04-22 2008-05-06 Wyeth Benzofuranyl alkanamine derivatives and uses thereof
CA2604915A1 (en) * 2005-04-22 2006-11-02 Wyeth New therapeutic combinations for the treatment or prevention of depression
AU2006239942A1 (en) * 2005-04-22 2006-11-02 Wyeth Dihydrobenzofuran derivatives and uses thereof
JP2009531436A (ja) * 2006-03-24 2009-09-03 ワイス 認知障害および他の障害の治療方法
EP2727585A1 (en) 2006-05-16 2014-05-07 Takeda Pharmaceutical Company Limited In-vivo screening method
EP2789338A3 (en) 2007-11-15 2015-01-14 Takeda Pharmaceutical Company Limited Condensed pyridine derivate and use thereof
EP2510949A4 (en) * 2009-12-11 2013-11-13 Astellas Pharma Inc THERAPEUTICS FOR FIBROMYALGIA
US20210052600A1 (en) 2017-12-27 2021-02-25 Takeda Pharmaceutical Company Limited Therapeutic agents for stress urinary incontinence and incotinence of feces

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9902267D0 (sv) * 1999-06-16 1999-06-16 Astra Ab New compounds
CA2465326C (en) * 2001-11-01 2011-03-29 Icagen, Inc. Pyrazolopyrimidines for decreasing ion flow through a voltage-dependent sodium channel
US20050261347A1 (en) * 2003-10-24 2005-11-24 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
US7435837B2 (en) * 2003-10-24 2008-10-14 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
US7728155B2 (en) * 2003-10-24 2010-06-01 Wyeth Llc Dihydrobenzofuranyl alkanamines and methods for using same as cns agents
GT200500296A (es) * 2004-10-21 2006-10-02 Sintesis asimetrica de derivados del dehidrobenzofurano
GT200500297A (es) * 2004-10-21 2006-10-27 Sintesis asimetrica de dehidrobenzofuranos sustituidos
EP1879875A1 (en) * 2005-04-22 2008-01-23 Wyeth Crystal forms opf {[(2r)-7-(2,6-dichlorophenyl)-5-fluoro-2,3-dihydro-1-benzofuran-2-yl]methyl}amine hydrochloride
TW200718692A (en) * 2005-04-22 2007-05-16 Wyeth Corp Dihydrobenzofuran derivatives and uses thereof
WO2006116221A2 (en) * 2005-04-22 2006-11-02 Wyeth Therapeutic combinations for the treatment or prevention of psychotic disorders
CA2605069A1 (en) * 2005-04-22 2006-11-02 Wyeth Treatment of drug abuse
US7368477B2 (en) * 2005-04-22 2008-05-06 Wyeth Benzofuranyl alkanamine derivatives and uses thereof
CA2604915A1 (en) * 2005-04-22 2006-11-02 Wyeth New therapeutic combinations for the treatment or prevention of depression
WO2006116165A1 (en) * 2005-04-22 2006-11-02 Wyeth Chromane and chromene derivatives and uses thereof
CA2605580A1 (en) * 2005-04-22 2006-11-02 Wyeth Benzodioxane and benzodioxolane derivatives and uses thereof
AR055916A1 (es) * 2005-04-22 2007-09-12 Wyeth Corp Derivados de dihidrobenzofurano, usos de los mismos en la preparacion de un medicamento y composicion farmaceutica
AU2006239942A1 (en) * 2005-04-22 2006-11-02 Wyeth Dihydrobenzofuran derivatives and uses thereof
US20060258712A1 (en) * 2005-04-24 2006-11-16 Wyeth Methods for modulating bladder function

Also Published As

Publication number Publication date
TW200639159A (en) 2006-11-16
JP2008538578A (ja) 2008-10-30
US20060258713A1 (en) 2006-11-16
MX2007013023A (es) 2007-12-13
AU2006239943A1 (en) 2006-11-02
CA2605117A1 (en) 2006-11-02
EP1871354A1 (en) 2008-01-02
GT200600160A (es) 2007-03-14
CN101189004A (zh) 2008-05-28
WO2006116171A1 (en) 2006-11-02

Similar Documents

Publication Publication Date Title
AR060089A1 (es) Tratamiento del dolor
BRPI0607536A2 (pt) tratamento de dor
BR112014015482A8 (pt) compostos carbamato de fenila para uso no alívio ou tratamento de dor e dor neuropática
BR112012009215A2 (pt) "terapia combinada contra o cancer com compostos inibidores de hsp90"
BRPI0411241A (pt) agentes terapêuticos úteis para o tratamento de dor
BR112015029491A2 (pt) derivados de imidazopirrolidinona e seu uso no tratamento de doença
BR0314699A (pt) Composto, composição e métodos para o tratamento da dor e para inibição da função vr1 em uma célula
EA201490279A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
AR044007A1 (es) Metodos para el tratamiento de la enfermedad de parkinson
BRPI0407375A (pt) Métodos para tratar dor por meio da administração de um antagonista do fator de crescimento neural e u nsaid e composições contendo os mesmos
PH12012501480A1 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
MX340965B (es) Combinaciones para el tratamiento de enfermedades que involucran la proliferacion celular.
BRPI0512213A (pt) método para tratamento, prevenção ou melhora de uma doença ou distúrbio; composição farmacêutica; processo para a preparação de um composto; e uso de um composto
BR112013029240A2 (pt) derivados deuterados do ivacaftor
BRPI0416656A (pt) compostos de pirrolopirimidina úteis no tratamento do cáncer
BRPI0415167A (pt) composto de amina como ligandos de canal de ìon e usos dos mesmos
BR112014000240A2 (pt) derivados de benzilamina como inibidores de calicreína plasmática
BRPI0406883A (pt) Composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto
BRPI0418166A (pt) compostos de bicicloeteroarilamina como ligandos de canal de ìon e usos destes
BR112015001502A2 (pt) derivados de tipo azaindazol ou diazaindazol para tratamento de dor
EA201490254A1 (ru) Комбинированное лечение гепатита с
MX2014001088A (es) Ciertos inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas, y metodos de uso de las mismas.
BR112014004741A2 (pt) pelo menos uma entidade química; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada
BR112012006010A2 (pt) composto de glicina
BR112012020377A2 (pt) utilização de um ou mais selecionado do grupo constituído por um composto da fórmula (i), uma mistura racêmica-diastereomérica e um isômero óptico do referido composto, e um sal farmaceuticamente aceitável e uma pródroga do mesmo, método, composição farmacêutica e kit para tratamento de caquexia e embalagem comercial

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired